Nxstage Medical, Inc. (NXTM)
-NasdaqGS | Prev Close: | 13.74 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 15.15 |
|---|
| Beta: | 0.64 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 10.15 - 17.15 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 309,153 |
|---|
| Market Cap: | 820.77M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.26 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Nxstage Medical announces new agreements with DaVitaBriefing.com(Tue, May 21)
- NxStage Announces New Agreements with DaVitaPR Newswire(Tue, May 21)
- NXSTAGE MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online(Tue, May 21)
- NXSTAGE MEDICAL, INC. FinancialsEDGAR Online Financials(Fri, May 10)
- NxStage Announces Second Quarter 2013 Investor Conference SchedulePR Newswire(Thu, May 9)
- 5 Healthcare Stock Earnings Snapshotsat Wall St. Cheat Sheet(Sat, May 4)
- NxStage Medical's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 2)
- Nxstage Medical Earnings: Here’s Why the Stock is Up Nowat Wall St. Cheat Sheet(Thu, May 2)
- NxStage Reports First Quarter 2013 Financial ResultsPR Newswire(Thu, May 2)
- Q1 2013 NxStage Medical, Inc. Earnings Release - Before Market OpenCCBN(Thu, May 2)
- NXSTAGE MEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhEDGAR Online(Thu, May 2)
- NxStage Medical Earnings Preview: Get Ahead of the Analystsat Wall St. Cheat Sheet(Wed, May 1)
- NxStage Announces FDA Clearance for New High Flow Capabilities with NxStage System OnePR Newswire(Tue, Apr 30)
- NxStage Names Robert G. Funari Chairman Of The BoardPR Newswire(Thu, Apr 25)
- NXSTAGE MEDICAL, INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Thu, Apr 25)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 3.33 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.26 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.07 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | -2.46 |
|---|
Business Summary
NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures.
View More